Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF’s action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with Kd = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many scaffolds suffer rapid clearance, metabolic instability, and uneven brain exposure [62,131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several proposed low molecular weight TrkB agonists have raised reproducibility and target specificity concerns, and central exposure remains difficult to optimize across scaffolds [131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundNeurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195 · cited 2×
“The binding affinity differs between these molecules, and BDNF and NT4 interact much stronger with TrkB than NT3 [31].”
BackgroundNeurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundBDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y.-A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,494 · cited 1×
“BDNF has antiapoptotic and neurotrophic properties affecting the viability and physiological condition of neurons [3,4].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“These may include side effects such as insomnia, sleepiness, and weight gain [10], and limited efficacy in drug-resistant forms of the disease [11].”
BackgroundConsiderations for the use of SH-SY5Y neuroblastoma cells in neurobiology
Kovalevich, J., & Langford, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-640-5_2 · Cited by 1,005 · cited 1×
“The SH-SY5Y cell line differentiated by retinoic acid (RA) is a widely used neuron-like model in neurobiological research [27].”
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207777 · Cited by 991 · cited 2×
“The cytoprotective effect of BDNF has been demonstrated in many in vitro and in vivo models [28].”
BackgroundBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Furthermore, BDNF appears to be a key transducer in mediating the therapeutic effects of known antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and ketamine, by inducing changes in neuroplasticity [9].”
BackgroundThe GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934 · cited 1×
“The interaction of the GABAA receptor was clinically proved to produce anxiolytic and antidepressant effects via reversing deficits in monoamine transmission in GABAergic machinery [42].”
BackgroundPharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783 · cited 1×
“A1A receptors reduce excitatory transmission by the regulation of potassium homeostasis, which leads to the inhibition of glutamate secretion in neuronal cells, whereas the A2A receptor modulates the sensitivity of the dopamine D2 receptor, typically in striatal neurons, which affects motoric functions [44].”
Background
Cited by
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions
Tessarollo, L., & Yanpallewar, S. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847572 · Cited by 89
Róg, T., Girych, M., & Bunker, A. (2021) · Pharmaceuticals · doi:10.3390/ph14101062 · Cited by 70
Unlocking Alzheimer’s Disease: The Role of BDNF Signaling in Neuropathology and Treatment
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Hemeda, L. R., Faheem, S. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08857-x · Cited by 59
“In addition, allosteric interaction with TrkB offers new opportunities, and a shift toward the crossed transmembrane domain of the TrkB receptor as a target for novel agonist pharmacophores should be considered in future development engaging the BDNF/TrkB signaling pathway (Pankiewicz et al., 2021).”
Neurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
TrkB transmembrane domain: bridging structural understanding with therapeutic strategy
Enkavi, G., Girych, M., Moliner, R., Vattulainen, I., & Castrén, E. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.02.001 · Cited by 44
Neuropharmacology of synaptic plasticity: pathways to cognitive resilience in healthy aging
Goel, F., Singh, P., Nand, S., & Yadav, D. K. (2026) · 3 Biotech · doi:10.1007/s13205-025-04673-z · Cited by 26
“Small molecule TrkB agonists including 7,8-DHF, were inspired to overcome some of the limitations of BDNF (Pankiewicz 2021).”
Targeting TrkB–PSD-95 coupling to mitigate neurological disorders
Yang, X., Huang, Y. A., & Marshall, J. J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02000 · Cited by 21
“…many TrkB agonists, including 7,8-DHF and LM22-A4, are reported to lack TrkB selectivity or do not activate TrkB signaling directly (Boltaev et al., 2017; Pankiewicz et al., 2021), suggesting these compounds act through mechanisms independent of direct TrkB activation (Boltaev et al., 2017).”
BackgroundLim, S. Y., & Cengiz, P. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109260 · Cited by 22
Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
“Both E2511 and ACD856 have been described as having no or very low agonistic effect on receptor function, but rather exert their action by modulating signaling [137,138,143,144].”
BackgroundSmall-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Ginsenosides can target brain-derived neurotrophic factor to improve Parkinson's disease
Ding, Y., Botchway, B. O. A., Zhang, Y., & Liu, X. (2023) · Food & Function · doi:10.1039/d2fo03484k · Cited by 13
Linking Hypothermia and Altered Metabolism with TrkB Activation
Alitalo, O., González-Hernández, G., Rosenholm, M., Kohtala, P., Matsui, N., Müller, H. K., Theilmann, W., Klein, A. B., Kärkkäinen, O. K., Rozov, S. V., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00350 · Cited by 11
Beresewicz, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105455 · Cited by 14
Antonijevic, M., Dallemagne, P., & Rochais, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380896 · Cited by 11
“What makes this quest even harder, is the debate currently existing in the field, in which the mechanism of action of some activators is questioned (Pankiewicz et al., 2021) (are the discovered small molecules actually direct activators of the TrkB receptor or are causing activation of it through…”
BackgroundProduction of brain-derived neurotrophic factor gates plasticity in developing visual cortex
Kaneko, M., & Stryker, M. P. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214833120 · Cited by 12
Brain neurotrophic factor BDNF: new data, functions and questions
Zhivkovich, M., Ermolaeva, E. V., Soboleva, A. V., Samoilova, E. M., Chudakova, D. A., & Baklaushev, V. P. (2024) · Genes and Cells · doi:10.17816/gc623163 · Cited by 9
Engberg, O., Roy, D. S., Krupa, P., Banerjee, S., Chaudhary, A., Smith, A. A., Li, M.-S., Maiti, S., & Huster, D. (2025) · Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c08750 · Cited by 7
Narboux‐Nême, N., Aouci, R., Fontaine, A., Vion, A., Levi, G., & Belz, L. (2024) · Cells · doi:10.3390/cells13151262 · Cited by 10
“D7S821 polymorphism linked to depression could therefore involve alterations in DLX5/6 locus expression.”
BackgroundBDNF mediates the heart-brain axis: implications for cardiovascular diseases and mental disorders
Fan, H., Duan, J., Liu, W., Yang, C., & Yang, L. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02016-w · Cited by 11
“Consequently, their efficacy and safety in large-scale clinical trials necessitate further rigorous validation [131].”
Stylianakis, A. A., Baker, K., & Richardson, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.822709 · Cited by 6
Neurotrophic Control of Puberty: From Molecular Signaling to Disorders of Pubertal Timing
Paparella, R., Iafrate, N., Lucibello, R., Bei, A., Bernabei, I., Fiorentini, C., Marchetti, L., Pastore, F., Maglione, V., Niceta, M., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb48010003 · Cited by 6
Nasehi, P., Omidkhah, N., & Ghodsi, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108950 · Cited by 6
7,8-Dihydroxyflavone is a direct inhibitor of human and murine pyridoxal phosphatase
Brenner, M., Zink, C., Witzinger, L., Keller, A., Hadamek, K., Bothe, S., Neuenschwander, M., Villmann, C., von Kries, J. P., Schindelin, H., et al. (2024) · eLife · doi:10.7554/elife.93094 · Cited by 4
“…assays to measure TrkB dimerization and activation, TrkB downstream signaling pathways, TrkB-dependent gene expression and cytoprotection, 7,8-DHF and other reported small-molecule TrkB agonists failed to activate TrkB in cells ( Boltaev et al., 2017 ; Pankiewicz et al., 2021 ; Todd et al., 2014 ).”
BackgroundDisruption of BDNF signalling in neuropathologies
Paulo-Ramos, A., Rhymes, E. R., Villarroel‐Campos, D., & Sleigh, J. N. (2026) · Biochemical Society Transactions · doi:10.1042/bst20253079 · Cited by 6
“Initial reports suggested direct TrkB binding and activation, but other studies have questioned whether 7,8-DHF achieves sufficient brain concentrations to directly activate TrkB, leaving the mechanism of action of TrkB agonists unresolved [153,154].”
Vecchi, J. T., Claussen, A. D., & Hansen, M. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1425226 · Cited by 3
7,8-dihydroxyflavone enhances long-term spatial memory and alters brain volume in wildtype mice
Rawlings-Mortimer, F., Lazari, A., Tisca, C., Tachrount, M., Martins-Bach, A. B., Miller, K. L., Lerch, J. P., & Johansen‐Berg, H. (2023) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2023.1134594 · Cited by 3
“Although much research has linked these drugs to BDNF agonism, there is evidence that suggests 7,8-dihydroxyflavone (7,8-DHF) may work through alternative mechanisms (Pankiewicz et al., 2021).”
BackgroundA fluorescent electrophile for CLIPS: self indicating TrkB binders
Thompson, T., Pewklang, T., Piyanuch, P., Wanichacheva, N., Kamkaew, A., & Burgess, K. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01654d · Cited by 3
Selective Modulation of Trk Receptors by Cyclo-Organopeptides
Joy, S., Mi, T., Lyu, R.-L., Pewklang, T., Thompson, T., Sefiani, A., Kamkaew, A., & Burgess, K. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00833 · Cited by 2
Rescue of Long-Term Spatial Memory by 7,8-Dihydroxyflavone in Mice with Reduced Oligodendrogenesis
Rawlings-Mortimer, F., & Johansen‐Berg, H. (2023) · eNeuro · doi:10.1523/eneuro.0498-22.2023 · Cited by 3
Zhou, Y., Feng, Y., Li, M., Xi, Y., Zhao, Y., & Chen, X. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110697 · Cited by 1
Selective, Intrinsically Fluorescent Trk Modulating Probes
Pewklang, T., Thompson, T., Sefiani, A., Geoffroy, C. G., Kamkaew, A., & Burgess, K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00290 · Cited by 2
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Physiological basis underlying antidepressant-induced activation of TrkB receptorsPreprint
Alitalo, O., Kohtala, S., Rosenholm, M., Kohtala, P., Saarreharju, R., Matsui, N., González-Hernández, G., Müller, H. K., Theilmann, W., Sarparanta, M. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458151
7,8-Dihydroxyflavone is a direct inhibitor of pyridoxal phosphatasePreprint
Brenner, M., Zink, C., Witzinger, L., Keller, A., Hadamek, K., Bothe, S., Neuenschwander, M., Villmann, C., von Kries, J. P., Schindelin, H., et al. (2023) · eLife · doi:10.1101/2023.10.04.560852
“However, a direct TrkB agonistic activity of 7,8-DHF has 80 been called into question (32-36).”
BackgroundRodrigues, É. F., Fachin, A. L., Marins, M., Letieri, F. B., Stábeli, R. G., & Beleboni, R. O. (2024) · Biotechnology Notes · doi:10.1016/j.biotno.2024.09.001
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Mikołajczyk, A., Popiel, D., Jastrzębska, K., Wiernicki, B., Mituła, F., Janusz, A., Dominowski, J., Górka, M., Kornatowski, T., Hucz‐Kalitowska, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1768167
“The experiment was conducted over 4 h at 37 ° C, following the protocol outlined in reference (Pankiewicz et al., 2021).”
Self-citationBacopa monnieri Promotes Neuronal Development by Regulating the Neurotrophin Signaling Pathway
Dash, R., Mitra, S., Dash, N., Barua, L., Mazumder, K., & Moon, I. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073048 · Cited by 1
“Although the overall Akt1 expression was not increased by BMEE treatment, BMEE increased Akt1 phosphorylation, suggesting that BMEE promotes Akt1 activation in a manner consistent with neurotrophin-mediated signaling [61,62].”
Patil, S. P., Kuehn, B. R., Schlosser, R., & Samohod, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750759
Turčić, M., & Vurušić, K. (2026) · Galician Medical Journal · doi:10.21802/e-gmj2026-a24
Metadata
- Authors
- Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., Smuga, D., Dominowski, J., Janusz, A., Górka, M., Abramski, K., Napiórkowska, A., Nowotny, M., Dubiel, K., Kalita, K., Wieczorek, M., Pieczykolan, J., & Matłoka, M.
- Affiliations
- Medical University of Warsaw (PL)
- Celon Pharma (Poland) (PL)
- Structural Biology Center, International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
- International Institute of Molecular and Cell Biology (PL)
- Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
- Corresponding author
- Matłoka, Mikołaj
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-07-21
- Volume
- 14
- Issue
- 8
- Pages
- 704
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8398766
- OpenAlex
- W3186036424
- Cited by
- 42
- References
- 54
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Badań i Rozwoju (POIR.01.02.00-00-0020/17-00)
- Ministerstwo Nauki i Szkolnictwa Wyższego (Doktorat Wdrożeniowy 50//DW/2017/01/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, orthosteric agonists, receptor activation, pharmacokinetics, pharmacodynamics, receptor dimerization, downstream signaling, compound library screening, target selectivity, receptor tyrosine kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.